Actively Recruiting
The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly
Led by IRCCS San Raffaele · Updated on 2024-09-19
100
Participants Needed
1
Research Sites
49 weeks
Total Duration
On this page
Sponsors
I
IRCCS San Raffaele
Lead Sponsor
U
University of Turin, Italy
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is an observational, retrospective, national multicenter study aimed to evaluate the impact and efficacy of Time To Switch (TTS) from first-line to second-line medical therapy in Acromegaly.
CONDITIONS
Official Title
The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult men and women aged 18 years or older with acromegaly
- Patients inadequately controlled with first generation somatostatin analogues (GH ≥1 µg/L and IGF-1 >1.3×ULN)
- Patients who switched to second line medical treatment (Pasireotide; Pegvisomant only; combination Pegvisomant + 1st generation SSA) after first-line treatment
- At least 12 months of follow-up during second-line therapy
- Signed informed consent to participate in the study
You will not qualify if you...
- Age under 18 years
- Pregnant or breastfeeding women
- Patients unable to understand or sign the informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Andrea Giustina
Milan, Italy, 20132
Actively Recruiting
Research Team
L
Luigi Di Filippo, medical doctor
CONTACT
G
Gabriela Felipe, clinical research nurse
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here